Meta-Analysis Finds Ecopipam Significantly Reduces Tic Severity in Tourette Syndrome

Bioengineer.org

Ecopipam significantly reduces tic severity in Tourette syndrome patients compared to placebo, as demonstrated by a meta-analysis showing a pooled mean difference of -3.72 points on the Yale Global Tic Severity Score. The analysis, which included data from 427 individuals across six publications, found consistent therapeutic benefits across all symptom domains with no significant heterogeneity. Safety assessments indicated similar tolerability between ecopipam and placebo, though some adverse events were more common with ecopipam.

Read at Bioengineer.org

All articles from 13 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.

Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.

More to read